Dublin, March 16, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Nanomedicine Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering. The Nanomedicine Market to Grow at a CAGR of 17.1% During the Forecast Period 2017-2023 to Aggregate $392.80 Billion By 2023
The nanomedicine market is analyzed based on two segments - therapeutic applications and regions.
The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas.
Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.
Key Topics Covered:
1 Industry Outlook 1.1 Industry Overview 1.2 Industry Trends 1.3 PEST Analysis 2 Report Outline 2.1 Report Scope 2.2 Report Summary 2.3 Research Methodology 2.4 Report Assumptions 3 Market Snapshot 3.1 Total Addressable Market (TAM) 3.2 Segmented Addressable Market (SAM) 3.3 Related Markets 3.3.1 mHealth Market 3.3.2 Healthcare Analytics Market 4 Market Outlook 4.1 Overview 4.2 Regulatory Bodies and Standards 4.3 Government Spending and Initiatives 4.4 Porter 5 (Five) Forces 5 Market Characteristics 5.1 Evolution 5.2 Ecosystem 5.2.1 Regulatory Process 5.2.2 Clinical Trials 5.2.3 Pricing and Reimbursement 5.3 Market Segmentation 5.4 Market Dynamics 5.4.1 Drivers 5.4.1.1 Emergence of nanorobotics 5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments 5.4.1.3 Reasonable investments in R&D 5.4.1.4 Increased support from governments 5.4.2 Restraints 5.4.2.1 Long approval process and stringent regulations 5.4.2.2 Problems regarding nanoscale manufacturing 5.4.2.3 Risks related to nanomedicines 5.4.2.4 Undefined regulatory standards 5.4.3 Opportunities 5.4.3.1 Aging population with chronic care needs 5.4.3.2 Population and income growth in emerging countries 5.4.4 DRO - Impact Analysis 6 Trends, Roadmap and Projects 6.1 Market Trends and Impact 6.2 Technology Roadmap 7 Types: Market Size and Analysis 7.1 Overview 7.2 Global Nanomedicine Market in Oncology Segment 7.3 Global Nanomedicine Market in Cardiovascular Segment 7.4 Global Nanomedicine Market in Neurology Segment 7.5 Global Nanomedicine Market in Anti-inflammatory Segment 7.6 Global Nanomedicine Market in Anti-infective Segment 7.7 Global Nanomedicine Market in Other Therapeutic Areas 8 Trending Nanomedicines 8.1 Overview 8.2 Abraxane 8.3 Alimta 8.4 Eligard 8.5 Copaxone 8.6 Rapamune 8.7 Neulasta 8.8 Cimzia 8.9 AmBisome 8.10 Mircera 8.11 Pegasys 8.12 Emend 8.13 Renagel 8.14 Ritalin 9 Regions: Market Size and Analysis 9.1 Overview 9.1.1 Global Nanomedicine Market by Geographical Segmentation 9.2 Key Leading Countries 9.2.1 US 9.2.2 Germany 9.2.3 Japan 10 Vendor Scenario 11 Vendor Profiles 11.1 Merck & Co. Inc. 11.2 Hoffmann-La Roche Ltd. 11.3 Gilead Sciences 11.4 Novartis AG 11.5 Amgen Inc. 12 Global Generalist 12.1 Pfizer Inc. 12.2 Eli Lilly and Company 12.3 Sanofi 13 Companies to Watch for 13.1 Nanobiotix SA 13.2 UCB SA 14 Market Landscape For more information about this report visit http://www.researchandmarkets.com/research/32hqk4/global
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Nanotechnology, Nanomedicine
